Superworth

P3 Health Partners profit margin PIII

Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.

Net margin, 12 months
−6.6%
Operating margin, 12 months
−9.9%
Net margin on a year earlier
+3.4 pts
Peer median
6.8%

Over the twelve months to Jun 30, 2026, P3 Health Partners kept −6.6% of its revenue as net profit, with an operating margin of −9.9%.

The median for 10 healthcare stocks of a similar size is 6.8%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−10.1%−18.5%
FY2024−9.1%−21.4%
FY2023−4.6%−13.3%
FY2022−25.7%n/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−6.6%+3.4 pts−9.9%
Q1 FY26−8.6%+0.7 pts−15.2%
Q4 FY25−10.1%−1.1 pts−18.5%
Q3 FY25−9.1%−2.1 pts−17.6%
Q2 FY25−10.0%−5.0 pts−21.7%
Q1 FY25−9.3%−4.3 pts−21.2%
Q4 FY24−9.1%−4.5 pts−21.4%
Q3 FY24−7.0%+3.8 pts−16.7%
Q2 FY24−5.0%+6.0 pts−12.3%
Q1 FY24−5.0%+20.0 pts−12.0%
Q4 FY23−4.6%+21.2 pts−13.3%
Q3 FY23−10.7%n/a−54.4%

Against its peers

Companies in Healthcare nearest P3 Health Partners' size, closest first, today.

CompanyProfit margin
PIIIP3 Health Partners−6.6%
NEPHNephros8.4%
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech6.8%
SPROSpero Therapeutics15.7%
LFVNLifevantage2.8%
ICCCImmucell2.6%
KEQUKewaunee Scientific3.0%
PDEXPro DEX17.6%
PLXProtalix BioTherapeutics23.5%
NATRNatures Sunshine Products3.7%
Peer median6.8%

Where P3 Health Partners ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on P3 Health Partners

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.